このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kringle Pharma マネジメント

マネジメント基準チェック /14

Kringle Pharma'sの CEO はKiichi Adachiで、 Dec2016年に任命され、の在任期間は 7.5年です。は、会社の株式の1.12%を直接所有しており、その価値は¥ 62.24M 。経営陣と取締役会の平均在任期間はそれぞれ1.5年と5.5年です。

主要情報

Kiichi Adachi

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	7.5yrs
CEOの所有権	1.1%
経営陣の平均在職期間	1.5yrs
取締役会の平均在任期間	5.5yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02

CEO（最高経営責任者

Kiichi Adachi (57 yo)

7.5yrs

在職期間

Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016. Kiichi Adachi serves as a Director of Kringle Pharma, Inc. since December 2005.Kiichi Adachi was Research Scientist...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kiichi Adachi	President & Director	7.5yrs	データなし	1.12% ¥ 61.2m
Tomoya Shimojo	Chief Financial Officer & Director of Accounting and Corporate Planning	no data	データなし	データなし
Kunio Matsumoto	Chief Scientific Officer	no data	データなし	データなし
Koichi Murakami	GM of Corporate Planning Management Department & Director	no data	データなし	データなし
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.5yrs	データなし	データなし
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	データなし	データなし

1.5yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: 4884の経営陣は経験豊富とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Kiichi Adachi	President & Director	18.5yrs	データなし	1.12% ¥ 61.2m
Koichi Murakami	GM of Corporate Planning Management Department & Director	2.5yrs	データなし	データなし
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.5yrs	データなし	データなし
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	データなし	データなし
Kohichiro Yoshino	Independent Outside Director	5.5yrs	データなし	データなし
Akihiro Tomoyasu	Part Time Director	7.5yrs	データなし	データなし
Kazuto Ninomiya	Audit & Supervisory Board Member	5.5yrs	データなし	データなし
Masahiro Motokawa	Audit & Supervisory Board Member	5.5yrs	データなし	データなし
Yosuke Yamaguchi	Audit & Supervisory Board Member	5.5yrs	データなし	データなし
Masato Fukui	Independent Outside Director	3.5yrs	データなし	データなし

5.5yrs

平均在職期間

52yo

平均年齢

経験豊富なボード: 4884の取締役会は経験豊富であると考えられます ( 5.5年の平均在任期間)。

Kringle Pharma マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

No independent directors

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024

Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)

First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)

Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar

Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

Kringle Pharma, Inc. Submits Clinical Trial Application

Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University

Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022

Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)

Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)

Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

No independent directors

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022

Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021

Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021

Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14